...
首页> 外文期刊>The Canadian journal of cardiology >The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.
【24h】

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.

机译:2005年加拿大高血压教育计划对高血压的管理建议:第二部分-治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To provide updated, evidence-based recommendations for the management of hypertension in adults. OPTIONS AND OUTCOMES: For lifestyle and pharmacological interventions, evidence from randomized controlled trials and systematic reviews of trials was preferentially reviewed. While changes in cardiovascular morbidity and mortality were the primary outcomes of interest, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the lack of long-term morbidity/mortality data in this field, and for certain comorbid conditions, other relevant outcomes, such as development of proteinuria or worsening of kidney function, were considered. EVIDENCE: MEDLINE searches were conducted from November 2003 to October 2004 to update the 2004 recommendations. Reference lists were scanned, experts were contacted, and the personal files of the subgroup members and authors were used to identify additional published studies. All relevant articles were reviewed and appraised independently, using prespecified levels of evidence, by content and methodology experts. As per previous years, only studies that had been published in the peer-reviewed literature were included; evidence from abstracts, conference presentations and unpublished personal communications was not included. RECOMMENDATIONS: Lifestyle modifications to prevent and/or treat hypertension include the following: perform 30 min to 60 min of aerobic exercise on four to seven days of the week; maintain a healthy body weight (body mass index of 18.5 kg/m2 to 24.9 kg/m2) and waist circumference (less than 102 cm for men and less than 88 cm for women); limit alcohol consumption to no more than 14 units per week in men or nine units per week in women; follow a reduced fat, low cholesterol diet with an adequate intake of potassium, magnesium and calcium; restrict salt intake; and consider stress management (in selected individuals). Treatment thresholds and targets should take into account each individual's global atherosclerotic risk, target organ damage and any comorbid conditions. Blood pressure should be lowered to 140/90 mmHg or less in all patients, and to 130/80 mmHg or less in those with diabetes mellitus or chronic kidney disease. Most adults with hypertension require more than one agent to achieve target blood pressures. For adults without compelling indications for other agents, initial therapy should include thiazide diuretics. Other agents appropriate for first-line therapy for diastolic hypertension with or without systolic hypertension include beta-blockers (in those younger than 60 years), angiotensin-converting enzyme (ACE) inhibitors (except in black patients), long-acting calcium channel blockers and angiotensin receptor antagonists. Other agents appropriate for first-line therapy for isolated systolic hypertension include long-acting dihydropyridine calcium channel blockers and angiotensin receptor antagonists. Certain comorbid conditions provide compelling indications for first-line use of other agents: in patients with angina, recent myocardial infarction or heart failure, beta-blockers and ACE inhibitors are recommended as first-line therapy; in patients with diabetes mellitus, ACE inhibitors or angiotensin receptor antagonists (or thiazides in patients with diabetes mellitus without albuminuria) are appropriate first-line therapies; and in patients with nondiabetic chronic kidney disease, ACE inhibitors are recommended. All hypertensive patients should have their fasting lipids screened, and those with dyslipidemia should be treated using the thresholds, targets and agents recommended by the Canadian Hypertension Education Program Working Group on the management of dyslipidemia and the prevention of cardiovascular disease. Selected patients with hypertension, but without dyslipidemia, should also receive statin therapy and/or acetylsalicylic acid therapy. VALIDATION: All recommendations were graded according to the strength of the
机译:目的:为成人高血压的治疗提供更新的,循证的建议。选择和结果:对于生活方式和药物干预,应优先回顾随机对照试验和试验系统评价的证据。心血管疾病发病率和死亡率的变化是人们关注的主要结果,但对于生活方式干预措施,由于该领域缺乏长期发病率/死亡率数据,对于某些合并症,其他原因也被认为降低血压是主要结果考虑了诸如蛋白尿的发展或肾功能恶化的结局。证据:MEDLINE搜索于2003年11月至2004年10月进行,以更新2004年的建议。扫描参考文献清单,联系专家,并使用亚组成员和作者的个人档案来确定其他已发表的研究。内容和方法专家使用预先指定的证据水平对所有相关文章进行了独立的审查和评估。与往年一样,仅包括经过同行评审的文献中已发表的研究。不包括摘要,会议演讲和未发表的个人通讯的证据。建议:改变生活方式以预防和/或治疗高血压包括以下内容:每周四至七天进行30分钟至60分钟的有氧运动;保持健康的体重(体重指数从18.5 kg / m2至24.9 kg / m2)和腰围(男性小于102厘米,女性小于88厘米);限制男性每周饮酒不超过14个单位,女性每周饮酒不超过9个单位;遵循减少脂肪,低胆固醇的饮食,并摄入足够的钾,镁和钙;限制盐的摄入;并考虑压力管理(在选定的个人中)。治疗阈值和目标应考虑每个人的整体动脉粥样硬化风险,目标器官损害和任何合并症。所有患者的血压均应降至140/90 mmHg或更低,而糖尿病或慢性肾脏病患者的血压应降至130/80 mmHg或更低。大多数成年人高血压需要一种以上的药物才能达到目标血压。对于没有令人信服的其他药物适应症的成年人,初始治疗应包括噻嗪类利尿剂。其他适用于一线治疗舒张压合并或不合并收缩期高血压的药物包括β受体阻滞剂(60岁以下),血管紧张素转换酶(ACE)抑制剂(黑人患者除外),长效钙通道阻滞剂和血管紧张素受体拮抗剂。适用于一线治疗孤立的收缩期高血压的其他药物包括长效二氢吡啶钙通道阻滞剂和血管紧张素受体拮抗剂。某些合并症为一线使用其他药物提供了令人信服的适应症:对于患有心绞痛,近期发生心肌梗塞或心力衰竭的患者,建议将β受体阻滞剂和ACE抑制剂作为一线治疗药物;在糖尿病患者中,ACE抑制剂或血管紧张素受体拮抗剂(或无蛋白尿的糖尿病患者中的噻嗪类)是适当的一线治疗;对于非糖尿病慢性肾脏病患者,建议使用ACE抑制剂。所有高血压患者均应进行空腹血脂检查,而血脂异常者应使用加拿大高血压教育计划血脂异常管理和预防心血管疾病工作组推荐的阈值,指标和药物治疗。选定的高血压但无血脂异常的患者也应接受他汀类药物治疗和/或乙酰水杨酸治疗。验证:所有建议均根据

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号